Joint Venture
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine for Opioid Use Disorder. Read more at www.ATAI.life
Team
Learn more about our management team, board of directors, and scientific advisors who are leading the effort to tackle opioid addiction. Read more.
DemeRx is a clinical stage pharmaceutical development company advancing two lead drug candidates as medication-assisted therapies for opioid addiction.
Our natural product lead drug – lbogaine – is an indole alkaloid from equatorial Africa, which blocks opioid withdrawal symptoms and drug cravings, helping drug dependent patients to transition to sobriety. The Company has developed a robust IP portfolio around Noribogaine, the principal active metabolite of lbogaine.